Markets

Celcuity Announces Commercial Availability Of REVTORPYK In U.S. For People With Hormone Receptor-Positive

Sep 30, 2026 · 08:05 AM ET· updated 1h ago

Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib) is

Why It Matters

Celcuity got approval to sell a new cancer medicine in the U.S. When a biotech company launches a new drug, watch if patients actually use it and if it makes money.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

CELC80.24

+2.86 (+3.69%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.